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Management of men with prostate cancer is fraught with uncertainty as physicians and patients balance
efﬁcacy with potential toxicity and diminished quality of life. Utilization of genomics as a prognostic
biomarker has improved the informed decision-making process by enabling more rationale treatment
choices. Recently investigations have begun to determine whether genomic information from tumor
transcriptome data can be used to impact clinical decision-making beyond prognosis. Here we discuss
the potential of genomics to alter management of a patient who presented with high-risk prostate
adenocarcinoma. We suggest that this information help selecting patients for advanced imaging, che-
motherapies, or clinical trial.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Case presentation
A 66-year old male with a family history of prostate cancer (PCa)
presented with weakened urinary stream, urinary tract infection
(UTI) and elevated PSA level of 51.8 ng/mL. Digital rectal examina-
tion (DRE) revealed a large nodule involving the entire left gland.
Biopsy was recommended but not performed due to noncompli-
ance. Continued blood work demonstrated a rising PSA (Fig. 1A).
Transrectal ultrasound guided biopsy performed a year after
presentation demonstrated 2/12 cores with Gleason 9 (5þ 4) and 3/
12 cores with Gleason 9 (4 þ 5). Preoperative pelvic MRI and bone
scan were negative for metastatic disease. The patient underwentncer Biology, and Urology,
Medical College at Thomas
South 11th St, Philadelphia,
).
access article under the CC BY-NCrobotic-assisted laparoscopic prostatectomy and bilateral pelvic
lymphadenectomywith pathology demonstrating Gleason 9 (5þ 4)
acinar adenocarcinoma involving 70% of the gland, positive surgical
margins, lymphovascular invasion, extracapsular extension, and 13
negative nodes (pT3a pN0).
Light microscopy revealed poorly differentiated areas of tumor
with neuroendocrine (NE) appearance (Fig. 1B), but immunohisto-
chemistry was negative for traditional NE markers such as
chromogranin and synaptophysin, and markers for small cell
carcinoma (CD56 [NCAM1] and TTF-1).
The Decipher PCa classiﬁer (GenomeDx Biosciences, San Diego,
CA) prognostic test showed a 5-year risk of distant metastasis of
45.4%.1 Previous studies2 have indicated that patients with such
Decipher scores would experience 80% reduction in metastasis if
adjuvant as opposed to salvage radiation was administered, and
accordingly adjuvant radiation therapy was recommended.
Prior to initiation of post operative therapy, the patient
presented with lower back pain and pancytopenia. CT revealed
multiple lytic lesions throughout the lumbar spine and visualized-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Clinical course of patient. A) Timeline delineating PSA kinetics and surgeries in association with diagnostic testing. B) H&E and synaptophysin negative staining of
prostatectomy specimen. C) The Decipher test result showing a high risk of metastatic disease at 5 years.
Figure 2. A) MRI and nuclear medicine bone scan demonstrating diffuse widespread osseous metastases. B) Bone marrow with extensive necrosis, consistent with inﬁltrating tumor.
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Figure 3. GenomeDx GRID assay. Prognostic signatures and genes implicated in prostate cancer demonstrating aggressive proliferation and neuroendocrine features of
prostatectomy specimen.
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strated diffusely enhanced marrow replacement throughout the
thoracic and lumbar spines, visualized pelvis and ribs. Bone scan
showed diffuse metastatic bone disease in the axial and appen-
dicular skeleton. Bone marrow biopsy demonstrated extensive
necrosis, consistent withmetastatic carcinoma (Fig. 2B). The patient
received Degarelix but developed progressive thrombocytopenia.Pulse steroids were prescribed and his thrombocytopenia began to
stabilize. Palliative radiation therapy to L1-L5 was delivered and his
PSA decreased to 5.1 ng/mL.
This case highlights the concernwith under-treatment of men at
high-risk for metastatic progression. There are numerous points
regarding management to consider that in retrospect could have
altered his clinical course. First, his prognostic score showed an
H. Kim et al. / Urology Case Reports 9 (2016) 51e5454extremely high metastatic potential, yet standard imaging were
negative. This is the ideal patient for whom to integrate novel im-
aging such as PSMA or NaF-PET. Although these are costly
tests, with proper patient selection they may prove to be cost
effective. Second, this case highlights the importance of obtaining
prognostic features in the pre-treatment setting as opposed to post-
prostatectomy. This is the type of patient for whom a neoadjuvant
approach with either intensive androgen deprivation therapy or
chemotherapy may have been beneﬁcial. Clearly, this patient’s case
represents the cohort of men in whom aggressive pre-operative
approaches are critical. Third, this case highlights the potential for
treating very aggressive localized disease using a metastatic
paradigm.
DNA sequencing of a panel of 315 pan-oncology genes was
performed and revealed equivocal ampliﬁcation of MDM4, MCL1
and PI3KC2B genes (FoundationOne, Foundation Medicine,
Cambridge, MA). These were not clinically actionable targets.
Comprehensive RNA expression analysis (Decipher GRID,
GenomeDx Biosciences, San Diego, CA, ClinicalTrials.gov number
NCT02609269) was used to evaluate 41 PCa disease signatures re-
ported in literature and the expression of 698 pan-oncology genes.
The results for this patient’s tumor were percentile ranked relative
to the GRID population of patient PCa expression proﬁles
(n ¼ 2293). Analysis of a panel of 17 prognostic signatures showed
the patient’s tumor had among the highest scores (Fig. 3).
Low expression of AR regulated genes such as KLK3 (0th
percentile), PCA3 (third), SRD5A1 (27th), NKX3.1 (34th) but average
expression of AR (56th) and KLK2 (58th) were observed. AR
signaling signatures proposed by Faisal et al3 (sixth) showed low AR
activity.
In contrast, high expression of neuroendocrine/small cell
genes such as CHGA (93rd), NKX2.1 (96th), MYCN (99th) but
loss of CCND1 (second) and RB1 (ninth) were observed. In
addition, three neuroendocrine/small cell signatures proposed
by Kumar et al4 (84th) and Alshalalfa et al5 (97th) suggest a
tumor expression proﬁle consistent with neuroendocrine
disease.
Among the panel of putative druggable targets in PCa, only the
target of checkpoint inhibitor PD1 (PDCD1, 90th) was found at high
expression. Finally, high expression of AKT3 (99th) detected on the
GRID and PIK3C2B ampliﬁcation on Foundation One, suggested
ampliﬁcation of chromosome 1q. Analysis from cBioPortal showed
that AKT3 is known to be ampliﬁed in 30% of castrate-resistant and
22% of neuroendocrine PCa.
Discussion
Genomics have advanced our understanding of the molecular
underpinnings of prostate cancer, but have just begun to inﬂuence
clinical decision making. This case illustrates how genomic analysis
can provide critical information regarding precision medicineclinical trials that is not available from clinicopathologic features
and highlights that despite the availability of genomics to identify
potentially actionable mutations, the breadth of clinical trials and
availability of molecular therapeutics is lagging. This chasm may be
mitigated through clinical trial designs such as the NCI-MATCH trial
(NCT02465060).
One of the promising tools generating genome-wide data for
PCa patients is the GRID. The GRID assessment evaluates the
relative expression of genes compared to a radical prostatectomy
population (>2000 patients) whose expression data has been de-
identiﬁed and anonymized. Currently, this is a tool for research
purposes, but as this case highlights has the opportunity to assist
physicians in rational selection of both clinical trials and standard of
care approaches for management in men with very high-risk dis-
ease. The ﬁndings from GRID and other such genomic assessments
will require validation, but as the ‘N of 1’ approach is increasing in
utilization within oncology, this platform provides a framework to
integrate it into localized prostate cancer.
Conclusion
This case report demonstrates how genomics and sequencing
are becoming available and can provide valuable data, while high-
lighting the lack of current translation into clinical applicability due
to (1) limited clinical trials available and (2) rapid clinical pro-
gression. Genomic data provide further evidence for rational
treatment approaches for selection of imaging, therapy, and
informed patient decision making.
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